Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study.

Arber N, Kuwada S, Leshno M, Sjodahl R, Hultcrantz R, Rex D; Exisulind Study Group.

Gut. 2006 Mar;55(3):367-73. Epub 2005 Sep 8.

2.

Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis.

Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, Fryer B, Church JM, Provencher K, Pamukcu R, Piazza G, Hawk E, Kelloff G, Elson P, van Stolk RU.

Adv Exp Med Biol. 1999;470:45-53.

PMID:
10709673
3.

Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.

[No authors listed]

Drugs R D. 2004;5(4):220-6. Review.

PMID:
15230629
4.

Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.

van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Kresty L, Kemmenoe BH, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd GT.

Clin Cancer Res. 2000 Jan;6(1):78-89.

5.

Exisulind Cell Pathways.

Griffiths GJ.

Curr Opin Investig Drugs. 2000 Nov;1(3):386-91. Review.

PMID:
11249724
6.

Effect of sulindac on sporadic colonic polyps.

Ladenheim J, Garcia G, Titzer D, Herzenberg H, Lavori P, Edson R, Omary MB.

Gastroenterology. 1995 Apr;108(4):1083-7.

PMID:
7698575
7.

Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy.

Goluboff ET, Prager D, Rukstalis D, Giantonio B, Madorsky M, Barken I, Weinstein IB, Partin AW, Olsson CA; UCLA Oncology Research Network.

J Urol. 2001 Sep;166(3):882-6.

PMID:
11490238
8.

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ.

N Engl J Med. 1993 May 6;328(18):1313-6.

9.

Sulindac causes regression of rectal polyps in familial adenomatous polyposis.

Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, Duhamel O, Trousset M, Attali P.

Gastroenterology. 1991 Sep;101(3):635-9.

PMID:
1650315
12.

Exisulind, a selective apoptotic antineoplastic drug.

Goluboff ET.

Expert Opin Investig Drugs. 2001 Oct;10(10):1875-82. Review.

PMID:
11772293
13.

Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.

Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, Hawk ET, Cohen DS, Ayers GD, Stephens LC; Familial Adenomatous Polyposis Study Group.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):920-7.

14.

Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.

Guldenschuh I, Hurlimann R, Muller A, Ammann R, Mullhaupt B, Dobbie Z, Zala GF, Flury R, Seelentag W, Roth J, Meyenberger C, Fried M, Hoppeler T, Spigelman AD, Scott RJ.

Dis Colon Rectum. 2001 Aug;44(8):1090-7; discussion 1097-9.

PMID:
11535846
15.
16.

Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?

Tonelli F, Valanzano R, Messerini L, Ficari F.

J Surg Oncol. 2000 May;74(1):15-20.

PMID:
10861602
17.

Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.

Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK.

JAMA. 2016 Mar 22-29;315(12):1266-75. doi: 10.1001/jama.2016.2522.

18.

[Sulindac in familial adenomatous polyposis coli--preliminary findings of a prospective study].

Müller A, Hürlimann R, Meyenberger C, Staub P, Kobler E, Ammann R.

Schweiz Med Wochenschr. 1994 Apr 16;124(15):651-4. German.

PMID:
8191270
19.

The safety and efficacy of celecoxib in children with familial adenomatous polyposis.

Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA.

Am J Gastroenterol. 2010 Jun;105(6):1437-43. doi: 10.1038/ajg.2009.758. Epub 2010 Mar 16.

PMID:
20234350
20.

[The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients].

Li J, Lv YM, Jin Z, Cui RL.

Beijing Da Xue Xue Bao. 2005 Aug 18;37(4):371-3. Chinese.

Supplemental Content

Support Center